Myriad Genetics, Inc. (MYGN)
| Market Cap | 289.82M -46.9% |
| Revenue (ttm) | 806.60M -3.2% |
| Net Income | -112.60M |
| EPS | -1.20 |
| Shares Out | 95.65M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,555,214 |
| Open | 3.170 |
| Previous Close | 3.170 |
| Day's Range | 3.010 - 3.180 |
| 52-Week Range | 2.740 - 8.590 |
| Beta | 1.67 |
| Analysts | Hold |
| Price Target | 4.09 (+34.98%) |
| Earnings Date | Jul 30, 2026 |
About MYGN
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion... [Read more]
Financial Performance
In 2025, Myriad Genetics's revenue was $824.50 million, a decrease of -1.56% compared to the previous year's $837.60 million. Losses were -$365.90 million, 187.4% more than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for MYGN stock is "Hold." The 12-month stock price target is $4.09, which is an increase of 34.98% from the latest price.
News
MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $MYGN--MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law.
Myriad Genetics, Inc. (MYGN) Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel
SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Myriad Genetics, Inc. (“Myriad Genetics” or the “Company”) (NASDAQ: MYGN) or certain of its officers and dire...
Myriad Genetics price target lowered to $3 from $5.50 at Wells Fargo
Wells Fargo lowered the firm’s price target on Myriad Genetics (MYGN) to $3 from $5.50 and keeps an Equal Weight rating on the shares. The firm notes shares were down…
Myriad Genetics price target lowered to $3.20 from $4 at BofA
BofA lowered the firm’s price target on Myriad Genetics (MYGN) to $3.20 from $4 and keeps an Underperform rating on the shares. The firm updated its estimates after the company’s…
Myriad Genetics price target lowered to $4 from $6 at TD Cowen
TD Cowen analyst Dan Brennan lowered the firm’s price target on Myriad Genetics (MYGN) to $4 from $6 and keeps a Hold rating on the shares. The firm said the…
Myriad Genetics cuts FY26 revenue view to $770M-$790M from $860M-$880M
Consensus $863.58M. Sees FY26 adjusted gross margin 66%-67%. The company said, “Revised the full-year 2026 revenue range lower, reflecting Q2 results and current business trends.”
Myriad Genetics reports Q2 EPS (25c), consensus (6c)
Reports Q2 revenue $190.7M, consensus $206.03M. “In the second quarter, we continued to make meaningful progress on the Cancer Care Continuum on a number of fronts, including 6% year-over-year volume…
Myriad Genetics Earnings Call Transcript: Q2 2026
Q2 2026 revenue fell 11% year-over-year to $190.7 million, driven by lower prenatal volumes and payer reimbursement friction, despite strong hereditary cancer and mental health test growth. Guidance for 2026 revenue and gross margin was lowered, and operational initiatives are underway to address reimbursement and efficiency challenges.
Myriad Genetics Earnings release: Q2 2026
Myriad Genetics released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Myriad Genetics Slides: Q2 2026
Myriad Genetics has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.
Myriad Genetics Quarterly report: Q2 2026
Myriad Genetics has published its Q2 2026 quarterly earnings report on July 30, 2026.
Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability
Highl ights Second quarter 2026 revenue of $190.7 million decreased 11% year-over-year, reflecting a 1% decline in volume and a 9% decrease in average revenue per test year-over-year. The company is e...
Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026
SALT LAKE CITY, July 23, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its second quarter 2026 earnings con...
Myriad Genetics Launches FirstGene® Multiple Prenatal Screen
Myriad Genetics Launches FirstGene® Multiple Prenatal Screen: The only lab test to run four prenatal genetic screens simultaneously as early as eight weeks
New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad's Prolaris® Biopsy Test in Localized Prostate Cancer
New published data shows Prolaris Biopsy Test adds significant prognostic information beyond conventional clinical risk categories for prostate cancer.
Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication
Publication of MONITOR-Breast study marks latest milestone for clinical validity of Precise MRD Publication of MONITOR-Breast study marks latest milestone for clinical validity of Precise MRD
Myriad Genetics Transcript: AGM 2026
The meeting covered director elections, auditor ratification, executive compensation, and equity plan approvals, with all proposals passing by majority vote. No stockholder questions were raised, and management highlighted risks associated with forward-looking statements.
Myriad Genetics appoints Raj Jampa as chief technology officer
Myriad Genetics (MYGN) announced the appointment of Raj Jampa as chief technology officer, effective June 1. As CTO, Jampa will be responsible for strategy and execution of Myriad’s technology organiz...
Myriad Genetics Names Raj Jampa as New Chief Technology Officer
SALT LAKE CITY, June 02, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announces today the appointment of Raj Jampa a...
Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting
SALT LAKE CITY, May 27, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announces it will share data demonstrating the ...
Myriad Genetics launches Prolaris + AI
Myriad Genetics (MYGN) announced the launch of the Prolaris + AI Test at the end of this month. Prolaris will be the first and only prostate cancer biomarker test to…
Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)
SALT LAKE CITY, May 26, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announces the launch of the Prolaris + AI Test ...
Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life
SALT LAKE CITY, May 15, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, joins forces with Nobody Wants This actress Jac...
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
SALT LAKE CITY, May 07, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced Myriad management will participa...
Myriad Genetics price target lowered to $6 from $7 at TD Cowen
TD Cowen lowered the firm’s price target on Myriad Genetics (MYGN) to $6 from $7 and keeps a Hold rating on the shares. The firm said Q1 results were a…